BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders
January 19 2022 - 4:57PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:
BCT) (“BriaCell” or the “Company”), is pleased to announce
that all resolutions proposed to shareholders at the Annual and
Special Meeting of Shareholders (the
“Meeting”)
held virtually via teleconference on January 18, 2022 were passed.
Voting for each of the director nominees was as follows:
Nominee |
For |
Withheld |
Actual |
Percentage |
Actual |
Percentage |
Dr. William V. Williams |
2,286,353 |
97.68% |
54,346 |
2.32% |
Mr. Jamieson Bondarenko |
2,286,214 |
97.67% |
54,485 |
2.33% |
Mr. Marc Lustig |
2,285,435 |
97.64% |
55,263 |
2.36% |
Dr. Rebecca Taub |
2,327,126 |
99.42% |
13,573 |
0.58% |
Mr. Vaughn C. Embro-Pantalony |
2,285,426 |
97.64% |
55,273 |
2.36% |
Mr. Martin Schmieg |
2,326,345 |
99.39% |
14,353 |
0.61% |
Dr. Jane Gross |
2,327,674 |
99.44% |
13,024 |
0.56% |
Shareholders also voted in favour of: (i)
setting the number of directors for the ensuing year at seven; (ii)
re-appointing MNP LLP as auditors of the Company; (iii) approving
the Company’s stock option plan; and (iv) approving an amendment to
the authorized share structure and articles of the Company by
creating a new class of subordinate voting shares, and to vary the
special rights and restrictions attached to the Common Shares to
reflect the creation of the new class of shares, as more
particularly described in the Company’s Management Information
Circular dated December 20, 2021 and posted to SEDAR on January 4,
2022. Please see the report of voting results filed under
BriaCell’s profile at www.sedar.com for the detailed results of
these other matters voted on by shareholders at the Meeting.
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully under the heading “Risks and Uncertainties” in the
Company’s most recent Management’s Discussion and Analysis, under
“Risks and Uncertainties” in the Company’s other filings with the
Canadian securities regulatory authorities and the U.S. Securities
and Exchange Commission, all of which are available under our
profiles on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information
except as required under applicable law.
Neither Toronto Stock Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
Toronto Stock Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Aug 2023 to Aug 2024